Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) EPS (Weighted Average and Diluted) (2020 - 2025)

Traws Pharma (TRAW) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 96.14% to -$0.34 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.71, a 96.69% increase, with the full-year FY2024 number at -$35.21, down 56.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.34 for Q3 2025 at Traws Pharma, down from -$0.11 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.09 in Q1 2025 to a low of -$20.52 in Q2 2024.
  • A 5-year average of -$3.23 and a median of -$0.27 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 10160.0% in 2024, then skyrocketed 135.3% in 2025.
  • Traws Pharma's EPS (Weighted Average and Diluted) stood at -$0.15 in 2021, then crashed by 73.33% to -$0.26 in 2022, then plummeted by 6226.92% to -$16.45 in 2023, then soared by 79.64% to -$3.35 in 2024, then skyrocketed by 89.85% to -$0.34 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's EPS (Weighted Average and Diluted) are -$0.34 (Q3 2025), -$0.11 (Q2 2025), and $2.09 (Q1 2025).